| Name | Title | Contact Details |
|---|
In 2015, an important group of investors alongside a group of experienced professionals in the Reinsurance industry, acquired a majority interest in MBI Americas. Now, XS Global, a well-known regional MGA and Coverholder at Lloyds. The groups footprint and ambitions now encompass the underwriting space, utilizing strong synergies that exist between the groups core business strategy. Our unique structure provides us opportunities to deploy targeted reinsurance capacity both directly to corporates and to retail brokers via expert and locally based underwriters. We are proud to say we invest in talent and our team has proven skills, excellent access, and a proven track record for underwriting profitable business in the Latin America region and beyond.
EMC Insurance Companies is among the top 60 insurance organizations in the country based on net written premium, and we have more than 2,500 employees. The company was organized in 1911 to write workers compensation protection in Iowa. Today, EMC provides property and casualty insurance products and services throughout the United States and writes reinsurance contracts worldwide. Operating under the trade name EMC Insurance Companies, Employers Mutual Casualty Company and one or more of its affiliated companies is licensed in all 50 states and the District of Columbia. Privacy Policy - https://www.emcins.com/misc/privacypolicy.aspx
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.